Naropin

Naropin is a local anaesthetic drug belonging to the amino amide group. The name ropivacaine refers to both the racemate and the marketed S-enantiomer. Naropin hydrochloride is commonly marketed by AstraZeneca under the trade name Naropin. .
[Wikipedia].

Naropin - Pharmacology:

Local anesthetics such as Naropin block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination and conduction velocity of affected nerve fibers.

Naropin mini report

Naropin NDA
NDA - A product marketed under an approved New Drug Application
Naropin EPIDURAL
EPIDURAL
Naropin EPIDURAL; INFILTRATION
EPIDURAL; INFILTRATION
Naropin EPIDURAL; INFILTRATION; PERINEURAL
EPIDURAL; INFILTRATION; PERINEURAL
Naropin EPIDURAL; PERINEURAL
EPIDURAL; PERINEURAL
Naropin INJECTION
INJECTION
Naropin INJECTION, SOLUTION
INJECTION, SOLUTION
Naropin HUMAN PRESCRIPTION DRUG
HUMAN PRESCRIPTION DRUG
Naropin global name
ROPIVACAINE HYDROCHLORIDE
Naropin global name
ROPIVACAINE HYDROCHLORIDE MONOHYDRATE
Naropin global name
ropivacaine hydrochloride
Start - Stop data
START DATA:
2009-Aug-04
Start - Stop data
STOP DATA
not occurred

Naropin for patients

When appropriate, patients should be informed in advance that they may experience temporary loss of sensation and motor activity in the anesthetized part of the body following proper administration of lumbar epidural anesthesia. Also, when appropriate, the physician should discuss other information including adverse reactions in the Naropin package insert.

Naropin Interactions

Naropin should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive. Cytochrome P4501A2 is involved in the formation of 3-hydroxy ropivacaine, the major metabolite. In vivo, the plasma clearance of ropivacaine was reduced by 70% during coadministration of fluvoxamine (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor. Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Naropin, can interact with Naropin leading to increased ropivacaine plasma levels. Caution should be exercised when CYP1A2 inhibitors are coadministered. Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as theophylline and imipramine may also occur. Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.

Naropin Contraindications

Naropin is contraindicated in patients with a known hypersensitivity to ropivacaine or to any local anesthetic agent of the amide type.

Generic name, Overdose, Half Life Naropin, Food Interactions, Chemical, etc..

Naropin see also FDA report


Chemical structure:
N O N H H H H H H H H H H H H H H H H H H H H H H H H H H C17H26N2O 2D chemical structure C17H26N2O SVG | 2D structure Ropivacaine | 5-Methoxy-N,N-diisopropyltryptamine | chemical names, chemical properties, classification C17H26N2O